OTC Markets OTCPK - Delayed Quote USD

GNI Group Ltd. (GNIIF)

Compare
19.88 -1.93 (-8.85%)
At close: December 13 at 9:37:01 AM EST
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,647,847.00
26,010,571.00
17,418,966.00
12,690,246.00
9,773,862.00
Cost of Revenue
4,403,957.00
3,579,396.00
2,674,409.00
1,600,498.00
1,545,943.00
Gross Profit
19,243,890.00
22,431,175.00
14,744,556.00
11,089,748.00
8,227,918.00
Operating Expense
9,849,380.00
9,322,332.00
13,366,616.00
9,464,798.00
6,358,377.00
Operating Income
9,394,510.00
13,108,843.00
1,377,940.00
1,624,950.00
1,869,541.00
Net Non Operating Interest Income Expense
-1,218,131.00
-479,158.00
-610,052.00
-517,938.00
-63,628.00
Pretax Income
8,326,178.00
12,612,748.00
767,887.00
1,107,010.00
1,805,913.00
Tax Provision
2,910,024.00
3,108,669.00
1,636,139.00
1,051,767.00
440,007.00
Net Income Common Stockholders
6,765,523.00
8,094,202.00
388,825.00
1,066,185.00
1,258,127.00
Diluted NI Available to Com Stockholders
6,765,523.00
8,094,202.00
388,825.00
1,066,185.00
1,258,127.00
Basic EPS
141.18
169.50
8.19
22.72
28.96
Diluted EPS
137.12
165.56
8.11
22.08
28.04
Basic Average Shares
48,971.19
47,752.12
47,473.96
46,924.02
43,437.35
Diluted Average Shares
50,975.52
48,890.76
47,931.12
48,290.39
44,871.59
Total Operating Income as Reported
9,394,510.00
13,108,843.00
1,377,939.00
1,624,948.00
1,869,540.00
Total Expenses
14,253,337.00
12,901,728.00
16,041,025.00
11,065,296.00
7,904,320.00
Net Income from Continuing & Discontinued Operation
6,765,523.00
8,094,202.00
388,825.00
1,066,185.00
1,258,127.00
Normalized Income
6,765,523.00
8,094,202.00
388,825.00
1,066,185.00
1,258,127.00
Interest Income
836,882.00
771,527.00
259,835.00
129,960.00
46,074.00
Interest Expense
2,055,013.00
1,250,685.00
869,887.00
647,898.00
109,702.00
Net Interest Income
-1,218,131.00
-479,158.00
-610,052.00
-517,938.00
-63,628.00
EBIT
10,381,191.00
13,863,433.00
1,637,774.00
1,754,908.00
1,915,615.00
EBITDA
11,135,116.00
14,471,855.00
2,159,440.00
2,137,941.00
2,245,226.00
Reconciled Cost of Revenue
4,403,957.00
3,579,396.00
2,674,409.00
1,600,498.00
1,545,943.00
Reconciled Depreciation
753,925.00
608,422.00
521,666.00
383,033.00
329,611.00
Net Income from Continuing Operation Net Minority Interest
6,765,523.00
8,094,202.00
388,825.00
1,066,185.00
1,258,127.00
Normalized EBITDA
11,135,116.00
14,471,855.00
2,159,440.00
2,137,941.00
2,245,226.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 10/24/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RKV.V Rakovina Therapeutics Inc.
0.1100
-21.43%
 
RGBP Regen BioPharma, Inc.
0.1000
+11.11%
 
BTAI BioXcel Therapeutics, Inc.
0.4121
+0.54%
 
ENTO Entero Therapeutics, Inc.
0.5839
-5.81%
 
XCUR Exicure, Inc.
17.31
-1.09%
 
PBM Psyence Biomedical Ltd.
1.8500
-9.31%
 
CDIO Cardio Diagnostics Holdings, Inc.
1.2600
+5.00%